Market Research Reports and Industry Reports

Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Macro Analysis

Performance of the Mature Biotech companies recommended by MP Advisors
in 2012 -report card is very impressive and we expect the positive sentiments
to prevail in 2013 and beyond
Valuation Multiples and Fundamentals- Drivers of Growth.
MP Advisors Proprietary Sum-of-The-Parts Valuation and Top Picks for 2013
Drug Approvals 2012-15
Key Milestones During 2013/14
Impact on revenue 2012-2017 from Patent Expiry and Strategies deployed to
meet the challenges.
Pipeline of Biosimilar mAbs
Joint Ventures between innovators and biosimilar players
Merger & Acquisitions Forecast- 2013-2020

In-depth Company Analysis
1. Acorda (ACOR)
1.1. Continuing Growth in AMPYRAs Sales
1.2. Ex. US Sales Risk Factored in the Current Price
1.3. Pipeline Beyond AMPYRA AC105, diazepam
1.4. Takeover target
1.5. Sum of the parts valuation
1.6. Background
2. Alexion (ALXN)
2.1. Product Pipeline Future Potential
2.2. Soliris in PNH and aHUS: Growth to Continue
2.3. Soliris beyond PNH and aHUS
2.4. Diversifying Beyond Soliris - Asfotase alfa, ALXN1102/ALXN1103,
ALXN1007
2.5. Sum of the parts valuation
3. Amgen (AMGN)
3.1. Investment Drivers
3.2. Pipeline Products Promising Progress, AMG145, Romosozumab
3.3. Enriched Pipeline through acquisitions or collaborations -
Blinatumomab, Talimogene laherparepvec, Omecamtiv mecarbil
3.4. Divest Pipeline Products Smartly
3.5. Tapping Emerging markets and other Geographical Expansion
3.6. Strategy for Biosimilars onslaught
3.7. Sum of the parts valuation
3.8. AHA 12 UPDATE: AMG 145 HYPERLIPIDEMIA
3.9. COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB HYPERLIPIDEMIABiogen Idec (BIIB)
4.1. Catalysts in the Next 6-8 Months BG-12, recombinant long-lasting
Factor VIII (rFVIIFc) and IX (rFIXFc), Obinutuzumab
4.2. March of Marketed Products Continues
4.3. Sum of the parts valuation
4.4. OBINUTUZUMAB: PHIII TRIALS
4.5. RITUXIMAB BIOSIMILAR PIPELINE
4.6. Other CNS drugs in the Pipeline
4.7. Biosimilar Development
5. Celgene (CELG)
5.1. Upcoming Key Milestones Pomalidomide, Apremilast, ABRAXANE
5.2. Negative Downside risk but not before 2019
5.3. Sum of the parts valuation
5.4. PROTEASOME INHIBITOR - CLINICAL DATA COMPARISON: R/R
MM
6. Gilead (GILD)
6.1. Advancements in the Anti-viral space HIV and HCV
6.2. Beyond Anti-Virals
6.3. Key Catalysts Sofosubivir, QUAD Pill, Elvitegravir
6.4. Competition from dolutegravir
6.5. Pipeline beyond anti-virals Ranexa, GS-1101 (PI3K inhibitor)
6.6. Sum of the parts valuation
6.7. KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION
6.8. DEVELOPMENT PIPELINE
7. Grifols (GRF)
7.1. Basis of OP recommendation
7.2. IVIG AD Opportunity A Wild Card but Not a Risk to its Core Business
7.3. Capacity Matters in Plasma Business
7.4. Weakness
7.5. BACKGROUND - BioScience Division, Diagnostic, Hospital
7.6. NEW PROTEINS IN DEVELOPMENT
7.7. FDA APPROVED PRODUCTS FRACTIONATED PLASMA
PRODUCTS
8. Onyx (ONXX)
8.1. Investments drivers Kyprolis, Oprozomab, Nexavar label expansion
8.2. Sum of the parts valuation
8.3. KYPROLIS: ASH 12 UPDATE
9. Regeneron (REGN)
9.1. Investments drivers
9.2. Upcoming Catalysts Marketed Products (Eylea, ZALTRAP)
9.3. Upside from Ex-Trap Late -stage Pipeline (REGN727/SAR236553,
Sarilumab, REGN475)
9.4. Sum of the parts valuation
9.5. COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB HYPERLIPIDEMIA
9.6. Commercializing strategy
9.7. Manufacturing and Global Supply Chain:
9.8. VASCEPA vs. LOVAZA & EPANOVA
9.9. CLINICAL DATA COMPARISON IN HYPERTRIGLYCERIDEMIA
VASCEPA vs. LOVAZA & EPANOVAVertex (VRTX)
10.1. INCIVEK, KALYDECO Label Expansion Little to Bet On,
10.2. Development Plans for IFN-free Combination
10.3. Beyond HCV and CF VX-509m VX-787, VX-765
10.4. Sum of the parts valuation
10.5. KEY PIPELINE PRODUCTS: IFN-FREE COMBINATION
10.6. DEVELOPMENT PIPELINE
10.7. DATA FROM IFN-FREE COMBINATIONS

Industry Tables
Valuation Snapshots
Expected Drug Clinical Milestones
MB sector Selected M&A Activities
Marketed Products Potential
Pipeline Potential Thru 2017
Patent Expiry Impact On The Sector
Valuation Snapshots
Expected Drug Clinical Milestones
MB sector Selected M&A Activities
Marketed Products Potential
Pipeline Potential Thru 2017
Patent Expiry Impact On The Sector

List Of Tables

N/A

List Of Figures

Valuation Snapshots
Expected Drug Clinical Milestones
MB sector Selected M&A Activities
Marketed Products Potential
Pipeline Potential Thru 2017
Patent Expiry Impact On The Sector

Global Construction Chemicals Market, By Product Type (Concrete Admixtures, Waterproofing Chemicals, Protective Coatings, Adhesives, etc.), By End User (Infrastructure & Real Estate), By Region, Competition Forecast and Opportunities, 2012-2026

Global Construction Chemicals market which stood at USD24.07 Billion in 2016 is expected to witness significant growth through 2026, owing to the rising number of construction projects globally. Several infrastructure

USD 4000View Report

Global Trocars Detailed Analysis Report 2017-2022

This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it

USD 3250View Report

Global Pharmaceutical Autoclaves Sales Market Report 2017

In this report, the global Pharmaceutical Autoclaves market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing

USD 4000View Report

Global Pharmaceuticals Pouch Market Professional Survey Report 2017

This report studies Pharmaceuticals Pouch in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 2500
  • Site Licence    USD 5000
  • Enterprisewide Licence    USD 7500
$ 2500

Reports Details

Published Date : Jan 2013
No. of Pages :110
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube